In January 2018, Addex Therapeutics and Indivior PLC announced they entered a collaboration to get new GABAB positive allosteric modulator (PAM) compounds into patients to be evaluated for the treatment of addiction. Addex together with partners at the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) and other leading academic laboratories had previously generated compelling preclinical data with GABAB PAMs that lend support to this approach for the treatment of substance use disorders. In addition, the data lead to the award of a $5.3 million grant from NIDA to support human studies with a GABAB PAM.
Under the terms of the agreement signed with Indivior in January 2018, Addex received a $5 million upfront, and a minimum of $4 million research funding to discover novel GABAB PAM compounds. The company could receive up to $330 million of development, regulatory and commercialization milestones and tiered royalties up to double-digit.
Addex retains the right to select compounds from the research collaboration for certain indications outside addiction, including Charcot-Marie-Tooth type 1a neuropathy (CMT1A).